<DOC>
	<DOCNO>NCT02764281</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety methotrexate , etoposide , pegaspargase dexamethasone ( MEDA ) chemotherapy autologous hematopoietic stem cell transplantation ( Auto-HSCT ) patient stage IV extranodal natural killer/T-cell lymphoma , nasal type .</brief_summary>
	<brief_title>MEDA Chemotherapy Autologous Hematopoietic Stem Cell Transplantation Stage IV Natural Killer/T-cell Lymphoma</brief_title>
	<detailed_description>Extranodal natural killer/T-cell lymphoma ( ENKTCL ) , nasal type , rare subtype non-Hodgkin lymphoma ( NHL ) relatively high incidence China . L-asparaginase base chemotherapy improve overall response prolong long-term survival patient stage IV . But optimal treatment schedule establish . This study design four cycle MEDA chemotherapy , follow Auto-HSCT stage IV patient newly onset , relapse refractory disease . The efficacy safety protocol treatment measure .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Pathological diagnosis extranodal natural killer/Tcell lymphoma , nasal type base WHO 2008 classification tumor haematopoietic lymphoid tissue . Eastern Cooperative Oncology Group ( ECOG ) performance status 0~3 . Stage IV disease least one measurable lesion . Preserved organ function : Platelet &gt; 20×109/L , hemoglobin &gt; 60g/L , total bilirubin ( TBIL ) &lt; 5×ULN , alanine transaminase ( ALT ) &lt; 5×ULN , normal serum creatinine , fibrinogen≥0.5g/L , LVEF≥50 % . No history chemotherapy radiotherapy solid cancer . Signed Informed consent . Relapsed progressive disease within 6 month prior Lasparaginasebased chemotherapy . Concurrent cancer need surgery chemotherapy within 6 month . History radiotherapy upperaerodigestive tract within last 3 month . Significant complication : LVEF≤50 % , coagulopathy , autoimmune disease , severe infection , liver cirrhosis , hemophagocytic lymphohistiocytosis . Mental disorder . Pregnant lactation . HIV , hepatitis virus C ( HCV ) , active hepatitis virus B ( HBV ) infection HBV DNA≥105 copies/ml . History pancreatitis . Known history grade 3/4 allergy drug chemotherapy regimen . Enrolled trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>